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ABSTRACT 
It has been shown that oxidative stress may play an important role in the development of 
atherosclerosis and carvedilol has the capacity of reducing oxidative stress. Accordingly, we 
assessed the hypothesis that carvedilol may reduce the severity of atherosclerosis in 
apolipoprotein (apo) E-deficient mice in addition to its hemodynamic effects. Atherosclerosis 
was induced in apo E-deficient mice fed a high fat diet containing 0.3 % cholesterol. Mice 
were orally treated with propranolol (30mg/kg/day), metoprolol (75mg/kg/day), and 
carvedilol (10mg/kg/day) over 8 weeks (each group n=7~9). Fatty streak plaque developed in 
apo E-deficient mice, and was suppressed in mice treated with all the three drugs. The 




cells in the lesions were 
decreased by the treatment of the drugs, of which carvedilol was the most effective. In 
addition, carvedilol reduced superoxide production in aortic walls detected by ethidium 
staining. There were no significant changes in blood pressure among the study groups. The 
heart rates in the treated groups were decreased by 4 % to 12 % compared with the control 
group with carvedilol yielding the highest suppression of heart rate. The β-blocker treatment 
did not significantly modify the serum lipid profiles. Carvedilol may suppress atherosclerosis 
via reducing superoxide production, in addition to the hemodynamic modifications in this 
animal model.  
Keywords: atherosclerosis; β-blockers; free radicals; carvedilol; superoxide 
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INTRODUCTION 
 Inflammation and many kind of stresses, especially oxidative stress and free radicals, 
may be considered to be key factors for the development of atherosclerosis.
1,2
 For example, 
angiotensin II is a major mediator of oxidative stress by activating NADH/NAD(P)H oxidase 
via the type 1 receptor, which results in the production of superoxide anion.
3, 4
 Thus, 
angiotensin II has deleterious effects on the vessel walls. Carvedilol, a multiple-functional 
neurohormonal antagonist, has been shown to provide a greater benefit than traditional β
-blockers in chronic heart failure because of its antioxidant actions that synergize with its 
nonspecific β- and α1-blocking effects
5
. When carvedilol and metoprolol were recently 
compared in clinical trials for heart failure, each showed beneficial β-blocking effects and 
decreased serum thiobarbituric acid reactive substance levels
6
. However, it was demonstrated 
that the superior cardioprotection of carvedilol to metoprolol and propranolol is induced by its 
anti-inflammatory action in ischemia and reperfusion models
7,8
.  Nevertheless, it largely 
remains to be determined how carvedilol protects against experimental atherosclerosis.   
 In the present study using apolipoprotein E-deficient mice, we have provided evidence 
for suppressive effects of atherosclerosis by carvedilol, focusing upon inhibitory effects for 
superoxide. In addition, to determine whether the effects of carvedilol are attributable solely 
to the hemodynamic effect or whether antioxidant property may also be involved, the effects 
of propranolol and metoprolol were also assessed in the same animal model. 
 
MATERIALS AND METHODS 
Experimental Atherosclerosis 
 The apolipoprotein E (apo E)-deficient 129ola×C57BL/6 hybrid mice were generous 
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gifts of Dr. Edward M. Rubin (University of California, Berkeley, CA). These mice were 
mated with C57BL/6 mice to produce F1 hybrids. The F1 apo E
+/-
 mice were then backcrossed 
to C57BL/6 mice for 10 generations. Mice homogeneous for the apo E-null allele on a 
C57BL/6 background were subsequently generated. Male mice were subjected to the 
subsequent experiments. The mice were kept in a temperature-controlled facility on a 
14:10-hour light-dark cycle with free access to food and water. 
 After being weaned at 4 weeks of age, mice were fed a normal chow diet (Oriental 
Yeast) until 6 weeks of age, when the animals were switched to a high fat diet containing 20% 
fat and 0.3% cholesterol as previously described.
9, 10
 
 The experimental protocols were approved by the institutional ethics committee for 
animal experiments of Kyoto University.  
Treatment Protocol 
 At 6 weeks of age, mice were orally treated via their drinking water with saline (control 
group, n=9), 30mg/kg/day of propranolol (propranolol group, n=9), 75mg/kg/day of 
metoprolol (metoprolol group, n=8), and 10 mg/kg/day of carvedilol (carvedilol group, n=7) 
for 8 weeks. The dosage of the drug was determined from the previous reports and the 
preliminary study.
11
 The blood pressure and heart rate were periodically determined by the 
tail-cuff method using a photoelectric cuff detection system (Softron BP-98A, Tokyo, Japan) 
as previously described.
11
 At 14 weeks the mice were killed by puncture of the ventricle under 
ether anesthesia. The organs were weighed, and the ratio of heart weight to body weight was 
calculated. 
Tissue Processing 
 Mice were killed by bleeding with puncture of the ventricle. The vasculature was 
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perfused with sterile phosphate buffered saline (PBS) and 6.8% sucrose. The root of the aorta 
was dissected under a microscope and frozen in OCT embedding medium for serial 
cryosectioning covering 1.0 mm of the root. The first section was harvested when the first 
cusp became visible in the lumen of the aorta. Four sections of 6 m thickness were harvested 
per slide, and thus 8 slides per mouse were prepared. All sections were immersed for 15 sec in 
60% isopropanol, stained for 30 min in a saturated oil-red-O solution at room temperature, 
counterstained with hematoxylin, and then mounted under coverslips with glycerol gelatin.
 
The oil red-O-stained sections were analyzed at a magnification of x10, as previously 
described.
 9,10 
The image was captured directly from the RGB camera attached to the light 
microscope and displayed on a microcomputer to quantify the cross-sectional surface area of 
the lesion and the cross-sectional surface area of the vessel. The fractional area of the lesion 
was calculated by dividing the whole vessel area, including the lumen intima, media and 




 To evaluate in situ superoxide production from the aorta, unfixed frozen cross sections 
of the specimens were stained with dihydroethidium (DHE; Molecular Probe, OR) according 
to the previously validated method.
12-14 
In the presence of superoxide, DHE is converted to 
the fluorescent molecule ethidium, which can then label nuclei by intercalating with DNA. 
Briefly, the unfixed frozen tissues were cut into 10-m thick sections, and incubated with 
10M DHE at 37C for 30 min in a light-protected humidified chamber. The images were 
obtained with a laser scanning confocal microscope. Superoxide production was demonstrated 
by red fluorescence labeling. 
 For quantification of ethidium fluorescence from aortas, fluorescence (intensity  area) 
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was measured using a high-power image. 
Immunohistochemistry 
 Anti-macrophage (anti-M, M 3/84, 1:400, PharMigen), anti-CD4(GK1.5, 1:50, 
PharMigen), and anti-CD8 (53-6.7, 1:50, PharMigen) antibodies were applied to 
acetone-fixed cryosections of aortic roots. After being washed, the sections were then exposed 
to second antibodies (horseradish peroxidase-conjugated or fluorescein 
isothiocyanate-conjugated antibodies), and the antibody binding was visualized with the so 
called diaminobenzidine method or under a fluorescence microscope. Sections were 
counterstained with methyl green or Mayer’s hemotoxylin if necessary. 
 The positive staining cells were counted in several fields at  400 magnification (within 
a 1-mm
2 
grid), and the percentages of the positive-staining cells / total infiltrating cells were 




 Serum was separated by centrifugation and stored at – 80C. Serum total cholesterol 
(TC) and triglyceride (TG) levels were measured. 
Statistical Analysis 
 Values were expressed as means  standard deviation (SD). Statistical analysis of the 
data was performed by one-way ANOVA, followed by the Fisher protected least- significant 
difference test. A value of P<0.05 was considered statistically significant. 
 
RESULTS 
Organ Weights (Table 1) 
 Heart weight to body weight ratios were not significantly different among the study 
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groups. 
Atherosclerotic Lesions (Table 2, Figure 1) 
 Apo E-deficient mice were kept on a cholesterol-rich diet for 8 weeks to induce fatty 
streak formation. The surface areas covered by fatty streak lesions were quantified in oil 
red-O-stained samples, and specimens from the control group were compared with those of 
β-blocker groups. Controls developed extensive lesions in the root of the aorta. In mice 
treated with β-blockers, the fraction area of lesions was reduced compared with the controls. 
Carvedilol suppressed the development of atherosclerosis the most of all the drugs. 
Superoxide Production (Table 2, Figure 1) 
 Ethidium fluorescence in the carvedilol group was significantly weaker than that in the 
control group as, specifically, the brightness of DHE-stained lesions from carvedilol treated 
mice was less than that from control mice. Metoprolol and propranolol treatment failed to 
suppress the superoxide production significantly compared with the control. By consideration 
with the previous report and the current study
13
, it may be that the origin of superoxide might 
be mainly from macrophages by their adjacent position, and partly from endothelial cells. 
Macrophage and T Cell Expression (Table 2, Figure 2) 




 T cells in the 
lesions were decreased by the treatment of the drugs compared with the control. 
Hemodynamics (Table 1) 
 The heart rates in the treated groups were significantly decreased by 4% to 12% 
compared with the control group with carvedilol producing the greatest suppression of heart 
rate. There were no significant changes in blood pressure among the study groups. The results 
suggested that the three drugs have almost the same β-blocking property. 
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Lipid Profiles (Table 3) 
 The drugs did not significantly modify the serum lipid profiles.  
 
DISCUSSION 
 The present findings clearly demonstrated that the three β-blockers showed almost the 
same extent of negative chronotropic effects upon apoE-deficient mice, that metoprolol and 
propranolol slightly reduced the severity of the disease, and that carvedilol markedly reduced 
the severity of atherosclerosis. The present results also showed that the superior 
cardioprotection of carvedilol over metoprolol and propranolol might be due to the 
suppression of tissue superoxide production.  
 There is increasing evidence to support the critical role of both free radicals and 
oxidative stress in the development of atherosclerosis
16-19.
 We have already demonstrated that 
MCI-186, a free radical scavenger and olmesartan, an angiotensin type 1 receptor antagonist, 
suppresses the severity of experimental atherosclerosis.
10
 Indeed, angiotensin stimulation has 
been reported to produce free radicals from various cells.
20
 Free radicals from vessel walls are 
thought to play critical roles in atherogenesis. It is considered that free radicals induce the 
expression of adhesion molecules and chemokines, accelerate atherosclerotic plaque 
formation, increase matrix metalloprotease production, and finally cause vulnerable plaques.
21 
Superoxide anion is one of free radical members. 
 Carvedilol blocks three (β１, β2, α1) adrenergic receptors and therefore possesses a 
more comprehensive sympatholytic action than other β-blockers.22,23  It is unlikely that the 
atheroprotective effects of carvedilol demonstrated in this study is achieved by β-receptor  
blocking action per se, because of the presence of such a protection by the metoprolol and 
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propranolol treatments. Although the present study did not precisely elucidate the role of  
α1-receptor blocking action per se, it is also unlikely thatα1 blockade is predominantly 
involved in the atheroprotection of carvedilol, because the vasodilatory effect of carvedilol is 
no longer prominent during chronic treatment.
11,24
 Recently, another new aspect of carvedilol 
regarding the inhibitory action against spontaneous Ca
2+ 
release of cardiac ryanodine receptor 
in heart failure has been reported.
25
 
 It is well known that heart rate reduction may play a protective role against the 
development of atherosclerosis.
26,27
 Concerning the relative doses of the three β-blockers 
used in the present study, we compare the drug effects at similar blood pressure levels. The 
three β -blockers presented almost the same negative chronotropic action. The 
anti-atherosclerotic effects of β-blockers in animal models were already reported in part, 
which were due to hemodynamic modification
28,29
 as well as anti-oxidative effects.
30,31
 In the 
present study, we clearly demonstrated that carvedilol suppressed not only the tissue 
superoxide production but macrophage accumulation with T cell expression in aortic walls. 
Immunohistochemical study showed that macrophage accumulation and the intensity of DHE 
staining in the aortic wall were very close. It has already been established that the degree of 
unstablity of plaques correlates with the amount of macrophages and T cell expression.
21
 Thus, 
the decrease of the intensity of macrophage and T cell expression in aortic walls may reflect 
the decrease of unstability of plaques by carvedilol treatment. 
 In conclusion, carvedilol treatment protects against experimental atherosclerosis in apo 
E-deficient mice by the suppression of superoxide production in the atherosclerotic lesions. 
The superior anti-atherosclerotic effects of carvedilol to metoprolol and propranolol may be 
attributed to the suppression of tissue superoxide production in addition to the hemodynamic 
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FIGURE LEGENDS 
Figure 1. Effects of β-blockers on atherosclerotic lesions and superoxide production 
The lesions in the drug-treated mice (B,C,D) were smaller and covered less inner 
circumference of the aortic root than those of the control mouse (arrows) (A). The 
intensity of ethidium fluorescence (white arrows) was less than that in control group 
( A ), suggesting less amount of superoxide production and the decrease of oxidative 
stress by the treatment. Carvedilol (D) was most effective. Insets boxes show 
magnified sample for DHE staining. 
            A= Control 
            B= Propranolol 
            C= Metoprolol 
            D= Carvedilol 
Oil-red-O stain( 40) 
                 DHE stain( 100) 
Figure 2. Effects ofβ-blockers on macrophage expression  
The expression of macrophages(M) (white arrow-heads) in the drug-treated groups 
(B,C,D) was less than that in control group(A).  
            A= Control 
            B= Propranolol 
            C= Metoprolol 




Table 1. Hemodynamics 
 
(MeanSD) 
*P<0.05 vs Control. 
HR, heart rate; SBP, systolic blood pressure; DBP, diastolic wood pressure HW, heat weight; BW, body weight. 
There were no statistical differences among the 3 β-blockers for each parameter. 
 








       Control 9 64445 1068 677 6.500.35 
Propranolol 9  58130* 10612 7111 5.880.45 
       Metoprolol 8 61656 10813 658 5.950.82 
       Carvedilol 7  56741* 11811 7011 6.840.60 
Table 2. Lesion Area 
 
(Mean±SD) 
*P<0.05,**P<0.01 vs Control.           
  Mφ,Macrophage. 
+Data were obtained by the number of positively stained cells by all the counterstained cells inside the  
  internal elastic lamina. Three to 5 random microscopic fields were analyzed at ×400. 
§For quantification of ethidium fluorescence, fluorescence(intensity × area) was measured using a high-power  
  image. Three to 5 microscope fields were analyzed. 




Lesion area, μm2 (%) 
Positive cells (%)+  
Ethidium fluolescence (units)§ Mφ CD4 CD8 
Control 9 110.1±59.5×103 (14.1±7.6) 25.3±5.3 27.0±9.6 12.6±4.2 1.00±0.09 
Propranolol 9 65.2±30.7×103  (8.4±3.9)* 15.5±4.8* 20.4±8.3 8.5±4.4 0.90±0.08 
Metoprolol 8 55.8±17.5×103  (7.2±2.2)** 16.2±3.5* 18.4±5.5 7.7±3.9 0.79±0.12 
Carvedilol 7 44.9±15.6×103  (5.7±2.0)** 4.2±4.0** 8.8±3.9** 5.7±4.2**   0.64±0.09* 
Table 3. Lipid Profiles 
 
(Mean±SD) 







Control 9 1382±232 40±18 
Propranolol 9 1504±265 33±14 
Metoprolol 8 1260±177 55±50 
Carvedilol 7 1405±349 
 
62±35 
